Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3.

Efficient methods were developed to synthesize a novel series of macrocyclic bisindolylmaleimides containing linkers with multiple heteroatoms. Potent inhibitors (single digit nanomolar IC(50)) for PKC-beta and GSK-3beta were identified, and compounds showed good selectivity over PKC-alpha, -gamma, -delta, -epsilon, and -zeta. Representative compound 5a also had high selectivity in a screening panel of 10 other protein kinases. In cell-based functional assays, several compounds effectively blocked interleukin-8 release induced by PKC-betaII and increased glycogen synthase activity by inhibiting GSK-3beta.

[1]  A. Reith,et al.  Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. , 2001 .

[2]  H. Eldar-Finkelman,et al.  The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes , 2002, Expert opinion on therapeutic targets.

[3]  Kirk W. Johnson,et al.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. , 2002, Diabetes.

[4]  Ana Martínez,et al.  Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs? , 2002 .

[5]  M. Jirousek,et al.  Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. , 1999, Current medicinal chemistry.

[6]  M. Faul,et al.  (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. , 1996, Journal of medicinal chemistry.

[7]  P. Traxler,et al.  ATP site‐directed competitive and irreversible inhibitors of protein kinases , 2000, Medicinal research reviews.

[8]  R. Jope,et al.  The multifaceted roles of glycogen synthase kinase 3β in cellular signaling , 2001, Progress in Neurobiology.

[9]  J W Yates,et al.  Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. , 2000, Chemistry & biology.

[10]  Kirk W. Johnson,et al.  Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. , 2002, Diabetes.

[11]  G. King,et al.  Protein kinase C and the development of diabetic vascular complications , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[12]  S. Emanuel,et al.  Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors. , 2003, Journal of medicinal chemistry.

[13]  M. Birnbaum,et al.  Regulation of Angiogenesis by Glycogen Synthase Kinase-3β* , 2002, The Journal of Biological Chemistry.

[14]  D. Cooper,et al.  Protein Kinases as Therapeutic Targets , 2000, Pharmaceutical Research.

[15]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[16]  M. Faul,et al.  Macrocyclic Bisindolylmaleimides: Synthesis by Inter- and Intramolecular Alkylation , 1998 .

[17]  J. Woodgett,et al.  Molecular cloning and expression of glycogen synthase kinase‐3/factor A. , 1990, The EMBO journal.

[18]  M. Faul,et al.  A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides , 1999 .

[19]  J. Tavaré,et al.  The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31‐8220) are potent inhibitors of glycogen synthase kinase‐3 activity , 1999, FEBS letters.

[20]  Ana Martínez,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[21]  S. Bursell,et al.  Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKC β Inhibitor , 1996, Science.

[22]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.

[23]  Kirk W. Johnson,et al.  Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. , 2003, Diabetes.

[24]  C. Pérez,et al.  First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[25]  H. Eldar-Finkelman,et al.  Glycogen synthase kinase 3: an emerging therapeutic target. , 2002, Trends in molecular medicine.

[26]  R. Zivin,et al.  Protection against glutamate toxicity through inhibition of the p44/42 mitogen-activated protein kinase pathway in neuronally differentiated P19 cells. , 2001, Biochemical pharmacology.

[27]  M. Jirousek,et al.  Protein kinase C inhibitors as novel anticancer drugs , 2001, Expert opinion on investigational drugs.

[28]  J. Woodgett,et al.  Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. , 2002, Advances in cancer research.

[29]  M. Saunders,et al.  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). , 2001, Bioorganic & medicinal chemistry letters.

[30]  J. Nuss,et al.  Current therapies and emerging targets for the treatment of diabetes. , 2001, Current pharmaceutical design.

[31]  William H Bullock,et al.  Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. , 2002, Current topics in medicinal chemistry.